TABLE 3.

Comparison of results of serodiagnostic tests for leptospirosis from selected validation studies with the rLipL32 ELISA

Assay	Evaluation site	No. of samplesa	% Sensitivityb		% Specificityc	Reference
			Acute phase	Convalescent phase
LipL32 IgG ELISA	Brazil	50	56	94	95
IgM ELISA	Barbados	92	52d	93	95–98	12
	Australia	41	42e	100	98	48
	Seychelles	90	38	68	97	50
IgM dipstick	Barbados	51	71	98	91	25
	Seychelles	90	39	68	96	50
	Multicenter	485	35–86f	69–100f	88–99f	43
	Multicenter	329	85	94	88–94	44
Latex agglutination	Netherlands	254	54	94	94	45
	Multicenter	137	38	88	95	45

^aLaboratory case-confirmation includes MAT, culture, and PCR evaluation. 

^bAcute-phase samples were collected from patients during the first 10 days of illness unless otherwise noted. Convalescent-phase samples were collected from patients following hospitalization. 

^cSpecificities are shown for groups of healthy individuals or nonleptospirosis patients. 

^dSamples collected at the time of hospital admission (median = 5 days) after onset of symptoms. 

^eFor samples collected 0 to 8 days after the onset of symptoms. 

^fMean sensitivity was 60% for acute-phase and 87% for convalescent-phase samples; mean specificity was 93%.